3 Key Takeaways
Plain English Summary- 01Core Finding
We found that mice bearing conditional deletion of Flt1 (encoding VEGFR-1) in T cells developed spontaneous obesity with advancing age.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
This Tfh-microbiota-obesity pathway was also observed in diet-induced obese mice and in humans. Oral administration of IgA reduced Taurinivorans and alleviated adiposity, highlighting the therapeutic potential of this axis. Tfh cell senescence impairs IgA production, disrupting gut microbial homeostasis, with consequences to host metabolic disease.
The Discovery
Autocrine signaling through vascular endothelial (blood-vessel lining) growth factor receptor-1 (VEGFR-1) reprograms T cell metabolism upon TCR stimulation. We found that mice bearing conditional deletion of Flt1 (encoding VEGFR-1) in T cells developed spontaneous obesity with advancing age. Analyses of lymphoid and metabolic tissues identified a VEGFR-1 + T follicular helper (Tfh) population in Peyer's patches and mesenteric lymph nodes. Flt1 deletion impaired Tfh fitness and reduced secretory IgA in the gut, resulting in unrestricted expansion of the pathobiont Taurinivorans. Taurinivorans overgrowth depleted host taurine, which drove obesity via suppressed adipocyte lipolysis and thermogenesis. Mechanistically, a VEGFR-1-AKT signaling axis promoted Tfh cell stemness by limiting p53-mediated senescence.
How It Works, Simply
This immunology research focuses on T cells · Receptor targeting · Signalling pathway. Researchers evaluated it using an in vivo animal model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
We found that mice bearing conditional deletion of Flt1 (encoding VEGFR-1) in T cells developed spontaneous obesity with advancing age.
- 02Study Evidence
Tested in a in vivo animal model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Animal models
In vivo animal model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
T cells · Receptor targeting · Signalling pathway
Intervention: Growth factor VEGF-B sustains intestinal Tfh cell stemness to restrict Taurinivorans
Experimental Findings & Endpoints
Autocrine signaling through vascular endothelial growth factor receptor-1 (VEGFR-1) reprograms T cell metabolism upon TCR stimulation.
We found that mice bearing conditional deletion of Flt1 (encoding VEGFR-1) in T cells developed spontaneous obesity with advancing age. Analyses of lymphoid and metabolic tissues identified a VEGFR-1 + T follicular helper (Tfh) population in Peyer's patches and mesenteric lymph nodes.
Flt1 deletion impaired Tfh fitness and reduced secretory IgA in the gut, resulting in unrestricted expansion of the pathobiont Taurinivorans. Taurinivorans overgrowth depleted host taurine, which drove obesity via suppressed adipocyte lipolysis and thermogenesis.
Mechanistically, a VEGFR-1-AKT signaling axis promoted Tfh cell stemness by limiting p53-mediated senescence.
Clinical Translation & Practice Context
This Tfh-microbiota-obesity pathway was also observed in diet-induced obese mice and in humans.
Oral administration of IgA reduced Taurinivorans and alleviated adiposity, highlighting the therapeutic potential of this axis. Tfh cell senescence impairs IgA production, disrupting gut microbial homeostasis, with consequences to host metabolic disease.
The Bottom Line · Clinical Pearl
“Tfh cell senescence impairs IgA production, disrupting gut microbial homeostasis, with consequences to host metabolic disease.”
Published in Immunity · Current Stage: Preclinical
